drugset
drugset / Trial / NCT04241458

A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321

NCT04241458 ↗

Phase 1 Completed 39 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 706321 in healthy male and female subjects following oral administration of multiple rising doses for 14 days.

Timeline

Start
2020-01-30
Primary completion
2020-11-24
Completion
2020-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 703621 Unknown 2 mg Oral
Subject BI 703621 Unknown 5 mg Oral
Subject BI 703621 Unknown 8 mg Oral
Subject BI 703621 Unknown 10 mg Oral
Subject Midazolam Small molecule 75 ug Oral

Indications

No indication recorded.